K.Raghavendra Rao, managing director, maintained that the inspection by the US FDA will commence in another 4-6 months. The fourth stage or the actual clinical test is being conducted in association with the Australian Healthcare major, Gleneagles. It is mentioned by Raghavendra Rao that the US FDA approval would pave for marketing the products through a US based generic company, which he did not name. All the four drugs will hit the market soon after the patents are awarded. It is perhaps for the first time in the country that a company has developed polymer-based drugs.
Polymer based drugs have only half the dosage of the original drug.
However it provides for the same or better results with less toxicity and side affects owing to the fact that the drug is delivered directly by the polymer compound to the diseased spot without any loss of drug in the transit. Apart from the above four new drugs developed, the company has also developed a new antibiotic drug based on the analogue research. Rao, while refusing to divulge details about the same, claimed that his company was also working on two more drugs based on the same method. We will be working on derivatives of the existing molecules to develop new drugs. For Process applications for a majority of drugs that it has in its stable aiming at paving way for the company to have a dominant role in patent-free regime.